Stock market premiere for Bactiguard

The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid Clouds were previously listed on the Nasdaq First North Growth Market in Iceland, but neither counted Icelandic VC’s as investors when going public. The same […]

Zealand Pharma has given formal notice to Nasdaq of the company’s intention to voluntarily remove its American Depositary Shares (ADSs) from listing on the New York-based Nasdaq Global Select Market. One ADS currently represents one ordinary share in Zealand Pharma, and today the company’s ADSs account for less than 1.5% of the total share capital. […]

Alvotech and Oaktree Acquisition Corp II, a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, have entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.” “Alvotech is in a unique position to impact the […]

Devyser Diagnostics has announced its intention to launch an initial public offering of its shares and to list its shares on Nasdaq First North Premier Growth Market. The offering is expected to consist of both new shares issued by Devyser and of existing shares in the company. Nasdaq has announced that the company meets the […]

Qlucore has received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares was 5th November 2021. Trading will be done with the ticker QCORE. “This paves the way for a new phase in Qlucore’s development. With the funding from the […]

Last week Senzime’s shares were admitted for trading on Nasdaq Stockholm’s main market and NLS asked its CEO about leadership, being a female CEO and about Senzime’s achievements so far. Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by algorithms and sensors to closely monitor patients under anesthesia. The company’s system […]

Elicera Therapeutics has announced that the subscription period for the company’s new share issue prior to the planned listing on Nasdaq First North Growth Market began May 24 and runs until June 8. The new share issue consists of a directed issue of a maximum of 6,500,000 Units, each consisting of one (1) new share […]